NAD+ Cycle Length: Research Schedules, Breaks & Duration

There is no clinically established NAD+ cycle length for injectable NAD+. Human studies have used short and very different schedules, so the evidence does not support one standard 4-, 8-, or 12-week cycle.

The best way to answer "how long is an NAD+ cycle?" is to separate three things: schedules used in published human research, schedules used in clinics, and schedules shared in peptide communities. Those are not the same level of evidence.

No. NAD+ is not a peptide. Nicotinamide adenine dinucleotide is a dinucleotide coenzyme involved in redox reactions and cellular metabolism. Peptides are chains of amino acids.

Searches such as "NAD peptide cycle" and "NAD+ peptide cycle length" are common, so this guide answers that wording. The chemistry is still different. Calling NAD+ a peptide can also lead people to copy cycle rules from peptide compounds that do not apply to NAD+.

Human NAD+ studies do not converge on one cycle length. The schedules below were designed for different research questions and should be read as study designs, not interchangeable protocols.

This distinction matters because online NAD+ cycle pages often combine short clinical studies, clinic protocols, and community routines into one chart. That can make a common practice look more proven than it is.

For the specific search "NAD+ injection cycle length," the evidence-based answer is still that no standard duration has been validated. Direct injection research is newer and much thinner than the broader research on oral NAD+ precursors.

One 2026 pilot exposed participants to NAD+, nicotinamide riboside, or placebo by subcutaneous, intramuscular, or intravenous routes on three consecutive days, followed by a seven-day washout. That design can inform short-term tolerability research, but it does not prove that three days on and seven days off is an NAD+ cycle protocol.

Four-, eight-, and twelve-week NAD+ cycles appear often in clinic and community content. They are useful search terms, but they should not be presented as if human trials established those durations.

This is also why the answer to "how long should you cycle NAD+?" cannot be reduced to one number. The duration depends on what kind of evidence is being discussed, and current human injection data do not provide a universal endpoint.

A loading phase is a short period of higher-frequency exposure at the beginning of a schedule. A cycle usually means the full period from the first planned exposure through the end of that block. The terms are often mixed together online.

The 2026 retrospective Frontiers study is useful here. Clients received 500 mg IV on four consecutive days. The paper described this as a typical commercial "loading dose" recommended by the compounding pharmacy, then followed the clients for 30 days. The study did not test a standardized maintenance phase after those four days.

Human research has not shown that injectable NAD+ must be cycled on and off. There is also not enough long-term injectable research to say that continuous use is an established alternative.

That leaves an evidence gap. A planned cycle, a maintenance schedule, and continuous exposure are different research models. None should be called the proven standard for injectable NAD+ based on the current literature.

There is no established evidence-based break length between NAD+ injection cycles. A seven-day washout appears in a recent injection pilot, but that was part of the study design and safety follow-up. It was not validated as the ideal break between repeating NAD+ cycles.

Online schedules may describe one, two, or several weeks off after a cycle. Those gaps should be labeled as clinic or community practice unless the exact schedule is supported by a human study using the same compound, route, and research goal.

Route is one of the biggest reasons NAD+ cycle charts can be misleading. A slow IV infusion can last hours, while a subcutaneous or intramuscular injection is a bolus exposure. The amount delivered, peak concentration, tolerability, and study setting can all differ.

For dose-by-dose information, concentration math, vial sizes, and reconstitution, use the NAD+ protocol guide. This cycle page stays focused on duration, scheduling evidence, and how to interpret cycle claims.

Nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are NAD+ precursors. They are related to NAD+ metabolism, but they are not the same intervention as injecting NAD+ itself.

This matters for cycle length. A 2026 injectable NR study includes a much longer at-home phase, with subcutaneous NR given three times per week from day 10 through day 100. That longer schedule is NR evidence, not proof that direct NAD+ injections should follow a roughly 90-day cycle.

A useful NAD+ cycle chart should tell you where each schedule came from. Before treating a duration as evidence-based, check the details below.

This page uses published human evidence when possible and labels preprint or commercial practice separately. Community cycle lengths can explain why certain numbers appear in search results, but they do not replace clinical evidence.

Direct long-term injectable NAD+ research remains limited. The 2026 Frontiers retrospective study followed clients for 30 days after a four-day IV loading period and concluded that more research is needed on dosage and effectiveness beyond 30 days.

That gap is important for 8-week, 12-week, and continuous-cycle searches. A longer calendar duration does not become evidence-based just because short studies show that NAD+ can be administered by injection or infusion.

Compounded drugs are not FDA-approved, and FDA has specifically warned compounders about the use of unsuitable food-grade NAD+ ingredients in sterile products. In 2026, FDA also cited an outsourcing facility for compounding NAD+ with a bulk drug substance that was not eligible for the section 503B exemptions described in that warning letter.

This regulatory context does not determine a cycle length, but it is another reason not to treat an online NAD+ injection schedule as an approved dosing standard.

Cycle length and dosage answer different questions. Cycle length is the total duration or structure of a research schedule. Dosage covers the amount per administration, frequency, concentration, vial math, and route-specific details.

Keeping these topics separate helps avoid turning this cycle guide into a duplicate of the main NAD+ dosage and protocol page.